Bio­phar­ma lead­ers con­demn mob vi­o­lence on Capi­tol Hill, look­ing to close Trump's chaot­ic chap­ter in Amer­i­can his­to­ry

Last week
Pharma

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

Last week
Deals
R&D

John Hood has found an­oth­er mis­fit drug to love — and bring back from the dead

Last week
R&D

EX­CLU­SIVE: Zai Lab’s Saman­tha Du scoops up Chi­na rights to an au­toim­mune drug with a hefty $175M li­cens­ing deal — heav­i­ly front­ed with cash and stock

Last week
Deals

New year, new me: Pfiz­er aban­dons icon­ic 'blue pil­l' lo­go in fa­vor of sleek­er — if more am­bigu­ous — new de­sign

Last week
Pharma

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

Last week
Deals
Pharma

Tim Lu’s quest to break new cell ther­a­py ground with gene cir­cuits gets Bay­er’s back­ing in a big new fi­nanc­ing round

Last week
Financing

Roche isn’t done lin­ing up new col­lab­o­ra­tions in the hot field of drug­ging RNA. Here’s one more

Last week
Deals

Roche gets a leg up in the an­ti-TIG­IT race with first break­through des­ig­na­tion for PhII win­ner tiragolum­ab

Last week
Regulatory

Re­gen­eron's Schleifer, Yan­copou­los set their com­pa­ny's am­bi­tions sky high with $1.4B on the ta­ble in per­for­mance awards

Last week
People

Mace Rothen­berg starts the year by step­ping out of his top job in Pfiz­er R&D — as Stan­ford’s Ai­da Habtezion steps in

Last week
People

In quick start to new year's M&A, Arvelle Ther­a­peu­tics hands reins to An­geli­ni as it nears EU ap­proval for cenoba­mate

Last week
Deals
R&D

2020’s NDA list is packed with com­mer­cial firsts — from his­toric to hap­haz­ard. Have we reached a tip­ping point?

Last week
Special

A $6B CVR goes pfffft as the game clock runs out on a New Year's dead­line for Bris­tol My­er­s' liso-cel ap­pli­ca­tion

3 weeks ago
Deals

The cu­ri­ous im­munol­o­gy be­hind the UK's sur­prise As­traZeneca dos­ing plan

3 weeks ago
R&D

Will they or won't they? The count­down on Bris­tol My­er­s' $6B CVR winds down to a hard dead­line at the FDA

3 weeks ago
R&D

Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ap­proval

3 weeks ago
Pharma
Regulatory

EU reg­u­la­tor says As­traZeneca ap­proval not im­mi­nent, even as Pas­cal So­ri­ot teas­es stronger da­ta

3 weeks ago
Pharma
Coronavirus

FDA lifts clin­i­cal hold on Au­den­tes' gene ther­a­py pro­gram af­ter three pa­tient deaths trig­gered alarms

3 weeks ago
Regulatory

News brief­ing: In­cyte bankrolls an ear­ly-stage myelofi­bro­sis pair-up with Jakafi; In­no­Care gets Chi­nese ap­proval for lead drug

3 weeks ago
News Briefing

Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with My­ovant

3 weeks ago
Deals

What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Here are the top 10

4 weeks ago
Editor's note

Vivek Ra­maswamy's 'van­t' brain­chil­dren keep bear­ing fruit with Urovan­t's FDA nod for in­con­ti­nence med vibegron

4 weeks ago
Regulatory

Al­tim­mune shares slide as the FDA flash­es a red light for the IND work on their in­tranasal Covid-19 vac­cine

4 weeks ago
Regulatory
First page Previous page 12345 Next page Last page